GlassScriptPhysician profile
Robin M Miller
NPI 1083915730
$3,509.17
in general payments reported to CMS, 2019-2025
21 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2021: $561 · 2022: $196 · 2023: $538 · 2024: $220 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,421 · Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,421.19 |
| Food and Beverage | $1,041.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,306.57 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Astrazeneca Pharmaceuticals LP | $418.33 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Abiomed | $196.93 | 2019 | |
| Novo Nordisk INC | $123.24 | 2019-2022 | |
| Lilly USA, LLC | $101.69 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $73.91 | 2021-2024 | |
| Abbvie INC. | $30.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.66 | 2021 | |
| Amgen INC. | $24.50 | 2023 | Repatha |
| Biohaven Pharmaceuticals, INC. | $21.10 | 2021 | |
| Vanda Pharmaceuticals INC. | $19.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.26 | 2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $19.15 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $18.46 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $16.75 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.98 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.10 | 2021 | |
| Dexcom, INC. | $14.21 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.